Edgewise Therapeutics, Inc. (EWTX)

Market Cap	1.49B
Revenue (ttm)	n/a
Net Income (ttm)	-100.16M
Shares Out	93.41M
EPS (ttm)	-1.57
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	605,170
Open	15.66
Previous Close	16.11
Day's Range	15.08 - 15.98
52-Week Range	5.12 - 20.69
Beta	0.15
Analysts	Strong Buy
Price Target	31.20 (+95.73%)
Earnings Date	May 9, 2024

About EWTX

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical tria...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 26, 2021
• Employees: 88
• Stock Exchange: NASDAQ
• Ticker Symbol: EWTX

Analyst Forecast

According to 5 analysts, the average rating for EWTX stock is "Strong Buy." The 12-month stock price forecast is $31.2, which is an increase of 95.73% from the latest price.

Price Target

$31.2

(95.73% upside)

Analyst Consensus: Strong Buy